152,867 Shares in Biogen Inc. (NASDAQ:BIIB) Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 152,867 shares of the biotechnology company's stock, valued at approximately $23,376,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.10% of Biogen at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Signaturefd LLC lifted its position in Biogen by 3.5% during the fourth quarter. Signaturefd LLC now owns 2,092 shares of the biotechnology company's stock valued at $320,000 after purchasing an additional 71 shares during the period. Quent Capital LLC lifted its position in Biogen by 31.9% during the fourth quarter. Quent Capital LLC now owns 298 shares of the biotechnology company's stock valued at $46,000 after purchasing an additional 72 shares during the period. Principal Securities Inc. increased its holdings in Biogen by 30.1% in the fourth quarter. Principal Securities Inc. now owns 337 shares of the biotechnology company's stock valued at $52,000 after buying an additional 78 shares in the last quarter. Israel Discount Bank of New York increased its holdings in Biogen by 6.2% in the fourth quarter. Israel Discount Bank of New York now owns 1,405 shares of the biotechnology company's stock valued at $215,000 after buying an additional 82 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators increased its holdings in Biogen by 5.7% in the fourth quarter. Deseret Mutual Benefit Administrators now owns 1,612 shares of the biotechnology company's stock valued at $247,000 after buying an additional 87 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Scotiabank cut their price objective on shares of Biogen from $244.00 to $224.00 and set a "sector outperform" rating for the company in a report on Thursday, February 13th. Oppenheimer set a $205.00 target price on shares of Biogen in a research note on Friday, May 2nd. Wells Fargo & Company cut their target price on shares of Biogen from $165.00 to $140.00 and set an "equal weight" rating for the company in a research note on Thursday, February 13th. HSBC cut shares of Biogen from a "buy" rating to a "hold" rating and set a $118.00 price objective for the company. in a research note on Monday, April 28th. Finally, Morgan Stanley decreased their target price on shares of Biogen from $157.00 to $152.00 and set an "equal weight" rating on the stock in a report on Wednesday, April 9th. Twenty investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $191.30.

Insider Transactions at Biogen

In related news, Director Stephen A. Sherwin sold 8,760 shares of the business's stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $150.02, for a total value of $1,314,175.20. Following the completion of the transaction, the director now directly owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Biogen Stock Performance

Shares of NASDAQ BIIB traded down $1.64 during trading hours on Friday, reaching $131.11. The stock had a trading volume of 3,640,026 shares, compared to its average volume of 1,413,436. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.35 and a quick ratio of 0.90. The business's fifty day moving average is $123.43 and its two-hundred day moving average is $139.43. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $238.00. The company has a market cap of $19.21 billion, a price-to-earnings ratio of 11.72, a PEG ratio of 1.51 and a beta of 0.12.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its earnings results on Thursday, May 1st. The biotechnology company reported $3.02 earnings per share for the quarter, missing analysts' consensus estimates of $3.26 by ($0.24). Biogen had a net margin of 16.87% and a return on equity of 14.98%. The business had revenue of $2.43 billion during the quarter, compared to analyst estimates of $2.25 billion. During the same quarter last year, the business posted $3.67 earnings per share. The business's quarterly revenue was up 6.2% compared to the same quarter last year. As a group, research analysts expect that Biogen Inc. will post 15.83 EPS for the current year.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.